Improving GLP-1 drug delivery by fusing the peptide directly to immunoglobulin antibodies owenhaskins Mar 24, 2025 3 min read Massachusetts Institute of Technology (MIT) researchers have revealed a drug delivery system that "paints" glucagon-like peptide-1 (GLP-1) directly onto the antibodies they target
Notably, considerable metabolic improvement was achieved at relatively low doses of GLP1/E, thus increasing the safety margin of this compound, which did not cause uterotrophic effects per se
BPC-157 has a short plasma half-life (on the order of minutes intravenously ) but its systemic effect exceeds pharmacokinetics, the mechanism acts via signalling cascades and transcription factors
10.2147/JIR.S350109 469 WangQ.LuoY.Ray ChaudhuriK.ReynoldsR.TanE.-K.PetterssonS
Both services ensure access to these medications through an easy online process, but Henry Meds also includes options for compounded medications, offering additional flexibility in treatment
e) Increased Cytokine and growth factor production by cytokines